Paper Details

  1. Home
  2. Paper Details

Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women.

Author: DonathFrank, HoffmannLarissa, NickischKlaus, Todorova-SanjariMarina, WarnkeAndré, WedemeyerRalph-Steven

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the effectiveness of a new vaginal ring containing tolterodine, a medication for overactive bladder, compared to oral extended-release tolterodine. The study found that the vaginal ring provided steadier and more consistent levels of tolterodine in the body than oral treatment, leading to fewer side effects. This suggests that the vaginal ring could be a promising new treatment option for overactive bladder, offering a more predictable and comfortable therapeutic experience.
Paper Details　
Original Abstract of the Article :
The aim was to assess the pharmacokinetics of tolterodine released from vaginal rings and of its active metabolite 5-hydroxymethyl tolterodine (5-HMT) compared to the respective pharmacokinetics resulting from oral administration of extended-release tolterodine in healthy, postmenopausal women. In t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cpdd.968

データ提供：米国国立医学図書館（NLM）

Intravaginal Tolterodine Formulation for Overactive Bladder Treatment: A Pilot Study

This pilot study investigates the pharmacokinetics of tolterodine delivered via vaginal rings compared to oral extended-release tolterodine in postmenopausal women with overactive bladder. The researchers aimed to determine if vaginal administration could provide a more consistent and predictable drug delivery, potentially reducing side effects. They found that vaginal rings releasing tolterodine produced steadier plasma concentrations, reducing the peak-trough fluctuations observed with oral administration. The vaginal rings also demonstrated good local tolerability, with the most common side effects being headache and dry mouth.

A New Oasis in the Desert of Overactive Bladder Treatment: A More Stable Approach

This study suggests that intravaginal tolterodine may offer a more effective and tolerable treatment option for overactive bladder, particularly for postmenopausal women. The steadier drug delivery provided by the vaginal rings could translate to a more consistent therapeutic effect and fewer side effects compared to oral administration. It's like creating a stable oasis in the desert of overactive bladder, providing a consistent source of relief and minimizing fluctuations.

Finding the Right Oasis for Overactive Bladder: A Personalized Journey

This research emphasizes the importance of exploring diverse treatment options to find the best approach for individual patients. It's like navigating a vast desert; the right path for one traveler may not be suitable for another. The results suggest that intravaginal tolterodine may offer a valuable alternative for patients who experience significant side effects or inconsistent response to oral medication.

Dr.Camel's Conclusion

This pilot study explores the potential of intravaginal tolterodine delivery for overactive bladder treatment. The results suggest that vaginal rings may provide a more stable and predictable drug delivery, potentially reducing side effects compared to oral administration. It's like discovering a new oasis in the desert, offering a more consistent source of relief for overactive bladder.

Date :
  1. Date Completed 2022-04-04
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34101369

DOI: Digital Object Identifier

10.1002/cpdd.968

Related Literature

Article Analysis
・Side Effects of tolterodine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.